SMC® technology allows researchers to push the limits of biomarker quantification, in some cases achieving single femtogram/mL detection. Here, we will present an overview of the SMC® technology and provide a case study for custom assay development.
For Research Use Only. Not For Use In Diagnostic Procedures.
Immunoassay Platform Solutions Specialist
Since 2016, Shane has covered immunoassay platforms, including ELISAs, MILLIPLEX® multiplex assays using the Luminex® xMAP® system, and the Single Molecule Counting (SMC®) platform, in the New York City metro area. Prior to this role, he was a research scientist at Memorial Sloan Kettering Cancer Center. Shane’s background is in immunology, and he did his graduate studies at Columbia University, followed by a post-doctoral fellowship at the University of Chicago.
Head of Custom Assays & Sample Testing
Sarah Hamren led the SMC® Custom Assay and Sample Testing group since 2015. She has over 30 years of experience in biopharma research and development. Previously the Director of Assay Development of the Life Science Division for Singulex® Inc., Sarah was responsible for the successful transfer of the Singulex® Life Science business unit since its 2015 acquisition. She is co-author on 15 peer-reviewed publications and holds two U.S. patents. Sarah’s 12 years of experience effectively partnering with a broad array of clients have culminated in hundreds of successful biomarker assay development projects. She has proven success overcoming the limitations of challenging sample types and very small sample volumes while at the same time adhering to project deadlines, budgets, and the highest standards of quality control.